Cargando…

Randomized dose-finding study of batefenterol via dry powder inhaler in patients with COPD

BACKGROUND: Batefenterol is a novel bifunctional muscarinic antagonist β(2)-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose–response of batefenterol and select a dose for Phase III d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crim, Courtney, Watkins, Michael L, Bateman, Eric D, Feldman, Gregory J, Schenkenberger, Isabelle, Kerwin, Edward M, Crawford, Catriona, Pudi, Krishna, Ho, Shuyen, Baidoo, Charlotte, Castro-Santamaria, Ramiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6413745/ https://www.ncbi.nlm.nih.gov/pubmed/30880951 http://dx.doi.org/10.2147/COPD.S190603

Ejemplares similares

A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
por: Crim, Courtney, et al.
Publicado: (2020)

Pharmacokinetics, Excretion, and Mass Balance of [(14)C]‐Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men
por: Ambery, Claire, et al.
Publicado: (2018)

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017)

Patients’ usability of seven most used dry-powder inhalers in COPD
por: Dal Negro, Roberto W., et al.
Publicado: (2019)

Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk
por: Covelli, Henry, et al.
Publicado: (2015)

Correction to: Patients’ usability of seven most used dry-powder inhalers in COPD
por: Dal Negro, Roberto W., et al.
Publicado: (2019)

Clinical recommendations for dry powder inhaler use in the management of COPD in primary care
por: Leving, Marika T., et al.
Publicado: (2022)

Factors associated with health status and exacerbations in COPD maintenance therapy with dry powder inhalers
por: W. H. Kocks, Janwillem, et al.
Publicado: (2022)

Effect of once-daily fluticasone furoate/vilanterol versus vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial
por: Maltais, Francois, et al.
Publicado: (2020)

Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD
por: Chapman, Kenneth R, et al.
Publicado: (2011)

Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD
por: Chetta, Alfredo, et al.
Publicado: (2021)

Budesonide–formoterol (inhalation powder) in the treatment of COPD
por: Ceylan, Erkan
Publicado: (2006)

Simultaneous Spray Drying for Combination Dry Powder Inhaler Formulations
por: Shepard, Kimberly B., et al.
Publicado: (2022)

Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD
por: Caramori, Gaetano, et al.
Publicado: (2014)

Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study
por: Zervas, Eleftherios, et al.
Publicado: (2016)

Do Face-to-Face Training and Telephonic Reminder Improve Dry Powder Inhaler Technique in Patients with COPD?
por: Poudel, Ramesh Sharma, et al.
Publicado: (2017)

Ciprofloxacin dry powder inhaler in cystic fibrosis
por: Elborn, J Stuart
Publicado: (2016)

Understanding the Importance of Capsules in Dry Powder Inhalers
por: Buttini, Francesca, et al.
Publicado: (2021)

Effect of Inhaler Design Variables on Paediatric Use of Dry Powder Inhalers
por: Lexmond, Anne J., et al.
Publicado: (2014)

Manipulation of Spray-Drying Conditions to Develop an Inhalable Ivermectin Dry Powder
por: Saha, Tushar, et al.
Publicado: (2022)

Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD
por: Svedsater, Henrik, et al.
Publicado: (2013)

In Vitro Dosing Performance of the ELLIPTA(®) Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™)
por: Hamilton, Melanie, et al.
Publicado: (2015)

Population Pharmacokinetics and Pharmacodynamics of GSK961081 (Batefenterol), a Muscarinic Antagonist and β(2)-Agonist, in Moderate-to-Severe COPD Patients: Substudy of a Randomized Trial
por: Ambery, Claire L., et al.
Publicado: (2015)

Usability and Robustness of the Wixela Inhub Dry Powder Inhaler
por: Allan, Richard, et al.
Publicado: (2021)

Radiolabeling Method for Lyophilizate for Dry Powder Inhalation Formulations
por: Miyamoto, Kahori, et al.
Publicado: (2022)

Feedback systems in multi-dose dry powder inhalers
por: Emeryk, Andrzej, et al.
Publicado: (2022)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
por: Han, Xiaoxuan, et al.
Publicado: (2023)

Effect of compression pressure on inhalation grade lactose as carrier for dry powder inhalations
por: Raut, Neha Sureshrao, et al.
Publicado: (2016)

Appropriate use of a dry powder inhaler based on inhalation flow pattern
por: Kondo, Tetsuri, et al.
Publicado: (2017)

An Overview on Spray-Drying of Protein-Loaded Polymeric Nanoparticles for Dry Powder Inhalation
por: Marante, Tânia, et al.
Publicado: (2020)

Inhalation treatment of primary lung cancer using liposomal curcumin dry powder inhalers
por: Zhang, Tongtong, et al.
Publicado: (2018)

Open‐Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently
por: Ambery, Claire, et al.
Publicado: (2018)

Influence of physical properties of carrier on the performance of dry powder inhalers
por: Peng, Tingting, et al.
Publicado: (2016)

Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering
por: Mehta, Piyush
Publicado: (2018)

Prerequisites for a dry powder inhaler for children with cystic fibrosis
por: Lexmond, Anne J., et al.
Publicado: (2017)

Recent advances in capsule-based dry powder inhaler technology
por: Lavorini, Federico, et al.
Publicado: (2017)

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation
por: Sibum, Imco, et al.
Publicado: (2019)

Spray Dried Formulations for Inhalation—Meaningful Characterisation of Powder Properties
por: Jüptner, Angelika, et al.
Publicado: (2019)

In vivo pharmacokinetic study of remdesivir dry powder for inhalation in hamsters
por: Sahakijpijarn, Sawittree, et al.
Publicado: (2021)

Amorphicity and Aerosolization of Soluplus-Based Inhalable Spray Dried Powders
por: Adhikari, Bishal Raj, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vc5v7r1heps5hlbhelse2uq8v8